Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): Anti-inflammatory and anti-cancer properties

Wellen, 2005, Inflammation, stress, and diabetes, J Clin Invest, 115, 1111, 10.1172/JCI200525102

Couzin-Frankel, 2010, Inflammation bares a dark side, Science, 330, 1621, 10.1126/science.330.6011.1621

Aggarwal, 2006, Inflammation and cancer: how hot is the link?, Biochem Pharmacol, 72, 1605, 10.1016/j.bcp.2006.06.029

Tracy, 2003, Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging, Int J Obes Relat Metab Disord, 27, S29, 10.1038/sj.ijo.0802497

Amor, 2010, Inflammation in neurodegenerative diseases, Immunology, 129, 154, 10.1111/j.1365-2567.2009.03225.x

Libby, 2006, Inflammation and cardiovascular disease mechanisms, Am J Clin Nutr, 83, 456S, 10.1093/ajcn/83.2.456S

Miller, 2009, Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression, Biol Psychiatry, 65, 732, 10.1016/j.biopsych.2008.11.029

Giuliani, 2001, Nf-kB transcription factor: role in the pathogenesis of inflammatory, autoimmune, and neoplastic diseases and therapy implications, Clin Ter, 152, 249

Tak, 2001, NF-kappaB: a key role in inflammatory diseases, J Clin Invest, 107, 7, 10.1172/JCI11830

Aggarwal, 2004, Nuclear factor-kappaB: the enemy within, Cancer Cell, 6, 203, 10.1016/j.ccr.2004.09.003

Baeuerle, 1996, NF-kappa B: ten years after, Cell, 87, 13, 10.1016/S0092-8674(00)81318-5

Chow, 1999, Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction, J Biol Chem, 274, 10689, 10.1074/jbc.274.16.10689

Lu, 2008, LPS/TLR4 signal transduction pathway, Cytokine, 42, 145, 10.1016/j.cyto.2008.01.006

Aderem, 2000, Toll-like receptors in the induction of the innate immune response, Nature, 406, 782, 10.1038/35021228

Ulevitch, 1999, Recognition of gram-negative bacteria and endotoxin by the innate immune system, Curr Opin Immunol, 11, 19, 10.1016/S0952-7915(99)80004-1

Jagetia, 2007, “Spicing up” of the immune system by curcumin, J Clin Immunol, 27, 19, 10.1007/s10875-006-9066-7

Shishodia, 2005, Curcumin: getting back to the roots, Ann N Y Acad Sci, 1056, 206, 10.1196/annals.1352.010

Aggarwal, 2009, Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases, Int J Biochem Cell Biol, 41, 40, 10.1016/j.biocel.2008.06.010

Goel, 2008, Curcumin as “Curecumin”: from kitchen to clinic, Biochem Pharmacol, 75, 787, 10.1016/j.bcp.2007.08.016

Aggarwal, 2009, Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets, Trends Pharmacol Sci, 30, 85, 10.1016/j.tips.2008.11.002

Anand, 2007, Bioavailability of curcumin: problems and promises, Mol Pharm, 4, 807, 10.1021/mp700113r

Hatcher, 2008, Curcumin: from ancient medicine to current clinical trials, Cell Mol Life Sci, 65, 1631, 10.1007/s00018-008-7452-4

Cheng, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res, 21, 2895

Dhillon, 2008, Phase II trial of curcumin in patients with advanced pancreatic cancer, Clin Cancer Res, 14, 4491, 10.1158/1078-0432.CCR-08-0024

Kasinski, 2008, Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin, Mol Pharmacol, 74, 654, 10.1124/mol.108.046201

Chen, 2002, Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages, J Immunol, 169, 6408, 10.4049/jimmunol.169.11.6408

Chen, 2006, Differential regulation of ARE-mediated TNFalpha and IL-1beta mRNA stability by lipopolysaccharide in RAW264.7 cells, Biochem Biophys Res Commun, 346, 160, 10.1016/j.bbrc.2006.05.093

Means, 2000, Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations, J Leukoc Biol, 67, 885, 10.1002/jlb.67.6.885

Shu, 2008, Radiosensitization of glioma cells with the curcumin analogs EF24 and UBS109

Dolcet, 2005, NF-kB in development and progression of human cancer, Virchows Arch, 446, 475, 10.1007/s00428-005-1264-9

Selvendiran, 2007, EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression, J Biol Chem, 282, 28609, 10.1074/jbc.M703796200

Holcomb, 2008, The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy, Pancreas, 36, 225, 10.1097/MPA.0b013e31815b3207

Adams, 2005, EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism, Anticancer Drugs, 16, 263, 10.1097/00001813-200503000-00005

Stambolic, 1998, Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN, Cell, 95, 29, 10.1016/S0092-8674(00)81780-8

Vasudevan, 2004, Suppression of PTEN expression by NF-kappa B prevents apoptosis, Mol Cell Biol, 24, 1007, 10.1128/MCB.24.3.1007-1021.2004

Sun, 2009, Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism, Bioorg Med Chem Lett, 19, 6627, 10.1016/j.bmcl.2009.10.023

Li, 2008, Cell death and proliferation in NF-kappaB p50 knockout mouse after cerebral ischemia, Brain Res, 1230, 281, 10.1016/j.brainres.2008.06.130

Camacho-Barquero, 2007, Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis, Int Immunopharmacol, 7, 333, 10.1016/j.intimp.2006.11.006

Chen, 1998, Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin, Oncogene, 17, 173, 10.1038/sj.onc.1201941

Nijboer, 2009, Alternate pathways preserve tumor necrosis factor-alpha production after nuclear factor-kappaB inhibition in neonatal cerebral hypoxia-ischemia, Stroke, 40, 3362, 10.1161/STROKEAHA.109.560250